Preeclampsia is a placentally induced hypertensive disorder of pregnancy that is associated with substantial morbidity and mortality to mothers and fetuses. Clinical manifestations of preterm preeclampsia result from excess circulating soluble vascular endothelial growth factor receptor FLT1 (sFLT1 or sVEGFR1) of placental origin. Here we identify short interfering RNAs (siRNAs) that selectively silence the three sFLT1 mRNA isoforms primarily responsible for placental overexpression of sFLT1 without reducing levels of full-length FLT1 mRNA. Full chemical stabilization in the context of hydrophobic modifications enabled productive siRNA accumulation in the placenta (up to 7% of injected dose) and reduced circulating sFLT1 in pregnant mice (up to 50%). In a baboon preeclampsia model, a single dose of siRNAs suppressed sFLT1 overexpression and clinical signs of preeclampsia. Our results demonstrate RNAi-based extrahepatic modulation of gene expression with nonformulated siRNAs in nonhuman primates and establish a path toward a new treatment paradigm for patients with preterm preeclampsia.
A r t i c l e s
Preeclampsia complicates 5-10% of all human pregnancies and causes nearly 76,000 maternal and 500,000 infant deaths globally each year. In the United States alone, preeclampsia is responsible for 100,000 premature births and 10,500 infant deaths annually, with aggregated costs of ~6.5-billion dollars to the health care system 1 (http://www.preeclampsia.org). Women with preeclampsia rapidly develop hypertension, often with proteinuria, usually after the 20th week of pregnancy. Maternal complications include kidney injury, HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome, seizure, stroke and death. Consequences for the fetus can be grave, ranging from intrauterine growth restriction to hypoxia-induced neurologic injury (for example, cerebral palsy) to death. Currently the only treatment option for women with preeclampsia is to deliver the fetusregardless of its gestational age-when the mother's symptoms become too severe. Thus, preeclampsia represents a substantial public health concern with an unmet clinical need.
Epidemiological and experimental studies indicate that the maternal signs and symptoms of preeclampsia that presents preterm are caused by abnormally high serum levels of sFLT1 proteins 2-10 -secreted antiangiogenic proteins that correspond to the extracellular domain of vascular endothelial growth factor receptor 1 (VEGFR1, also known as full-length FLT1). sFLT1 proteins scavenge circulating VEGF and placental growth factor and attenuate VEGF signaling by membrane-bound VEGF receptor FLT1 11, 12 . Circulating sFLT1 levels rapidly decrease after delivery of the placenta, and maternal preeclampsia signs usually resolve within 48 to 72 h, consistent with the placental origin of sFLT1 2, 13 . Serum sFLT1 levels are considered a diagnostic and prognostic marker of preeclampsia [14] [15] [16] [17] . Moreover, lowering sFLT1 and other circulating factors by apheresis-i.e., filtering maternal blood through a dextran sulfate column-can control both blood pressure and proteinuria and extend preeclamptic pregnancies 18, 19 . Thus, sFLT1 is a biologically validated and clinically promising therapeutic target for preeclampsia.
Short interfering RNA (siRNA) therapeutics are an emerging class of drugs that target nucleic acids 20 . The most clinically advanced siRNA technology comprises fully chemically stabilized siRNAs conjugated to N-acetylgalactosamine (GalNAc), which drives safe, efficient siRNA delivery to and long-lasting (6-to 9-month) silencing activity in liver 21, 22 . Whereas the utility of GalNAc chemistry is limited to hepatocytes, hydrophobic conjugates (for example, cholesterol) enable nonselective siRNA distribution to a range of tissues [23] [24] [25] [26] , favoring tissues with high blood flow and fenestrated endothelium. These tissue characteristics are shared by the placenta, suggesting that fully chemically modified, cholesterol-conjugated siRNAs 23, 24, 26, 27 might also accumulate in placenta and allow selective silencing of sFLT1.
rNAi modulation of placental sFlt1 for the treatment of preeclampsia A r t i c l e s As a first step toward developing siRNAs that selectively silence sFLT1 but not full-length FLT1, we recently analyzed the transcriptional profiles and 3′ ends of sFLT1 and FLT1 mRNAs in normal and preeclamptic placentas 28 . sFLT1 and FLT1 mRNAs are predominantly expressed in the placenta, with sFLT1 mRNA isoforms comprising as much as 97% of placental FLT1 mRNAs. Use of alternative polyadenylation sites in intron 13 and exon 15 gives rise to three dominant sFLT1 mRNA isoforms-sFLT1-i13 short, sFLT1-i13 long and sFLT1-e15a (Fig. 1a,b) -which all are upregulated in preeclamptic placentas 28 ( Supplementary Fig. 1 ). The unique 3′ ends of the sFLT1 isoforms offer an opportunity to selectively target sFLT1.
Here we identify siRNAs that selectively silence sFLT1 mRNAs without affecting full-length FLT1. Full chemical stabilization and cholesterol conjugation allow systemically delivered siRNAs to accumulate in mouse and baboon placentas, where they silence sFLT1 mRNA. Finally, we show that sFLT1-targeting siRNAs lower circulating sFLT1 protein and alleviate hypertension and proteinuria in a baboon model of preeclampsia. Taken together, these results provide a strong foundation for future development of an siRNA-based therapeutic for preeclampsia.
RESULTS
Screen to identify siRNAs selectively silencing i13 and e15 sFLT1 mRNA isoforms Three sFLT1 mRNA isoforms-sFLT1-i13 short, sFLT1-i13 long and sFLT1-e15a-predominantly contribute to the expression of sFLT1 protein, which circulates at high levels in patients with preterm preeclampsia 4, [28] [29] [30] . Thus all three isoforms need to be targeted to productively decrease the levels of circulating sFLT1 protein across the spectrum of preeclampsia. The sFLT1-i13 long and sFLT1-e15a mRNA isoforms contain 435 and 567 unique nucleotides, respectively, not present in full-length FLT1 mRNA, allowing selective targeting. We designed a panel of 26 siRNAs targeting essentially all possible regions in the two sFLT-i13 isoforms (sFLT1-i13 long includes the sequence of sFLT1-i13 short) and 21 siRNAs targeting sFLT1-e15a. The selection was favored, to the extent possible, to comply with conventional siRNA design parameters 31 that account for G+C content, specificity and low frequency of complementary seed sites in the genome 32 , and thermodynamic bias 33, 34 . Design criteria also favored siRNAs that target sites with perfect homology in nonhuman primates, to enable evaluation in a baboon preeclampsia model (see below).
For initial in vitro screening, we synthesized hydrophobically modified asymmetric siRNAs (hsiRNAs), which can be added directly to the cell medium-e.g., without lipid formulation. hsiRNAs are partially chemically modified for improved stability and composed of a 20-nucleotide (nt) guide strand base-paired to a 15-nt passenger strand, leaving a fully phosphorothioate-modified single-stranded tail at the 3′ end of the guide strand 23, 25, [35] [36] [37] . The phosphorothioated tail containing siRNAs is more potent in cellular uptake and sFLT1 silencing than fully duplexed (symmetrical) siRNAs 27 . The 3′ end of the passenger strand is conjugated to cholesterol, which promotes membrane intercalation and rapid, efficient internalization by all cell types 37, 38 , including primary trophoblasts. All sequences and chemical modification patterns used in this study are shown in Supplementary Table 1 .
To simplify the screening process, we generated luciferase-based reporters in which the sFLT1-i13 and sFLT1-e15a unique sequence regions were cloned downstream of the Renilla luciferase coding region. We then assayed the ability of each hsiRNA to reduce Renilla luciferase activity as a proxy for productive silencing of sFLT1-i13 and sFLT1-e15a. Primary screens identified several functional hsiRNAs that efficiently silenced sFLT1-i13 or sFLT1-e15a mRNA isoforms ( Fig. 1c,d ; see Online Methods). Based on dose-response studies of all functional hsiRNAs, we chose the top two hsiRNAs from each primary screen as lead configurations: hsiRNA sFLT1 -2283 and hsiR-NA sFLT1 -2318 for silencing of sFLT1-i13, and hsiRNA sFLT1 -2519 and hsiRNA sFLT1 -2585 for silencing sFLT1-e15a. The half-maximal inhibitory concentrations (IC 50 ) of selected compounds ranged from 50 to 90 nM (passive uptake), and their sequences and target positions are shown in Figure 1e -g.
To confirm that lead hsiRNAs efficiently silence sFLT1 mRNAs in a cell type relevant to preeclampsia, we used QuantiGene 2.0 assays that allowed specific and direct detection of human sFLT1-i13 and sFLT1-e15a mRNAs in human primary cytotrophoblasts, the placental cell type responsible for sFLT1 overexpression. Identified hsiRNAs silenced sFLT1 mRNAs in cytotrophoblasts, with IC 50 values comparable to those found in the reporter assay (50 to 70 nM; Fig. 1e,h,i) . Moreover, productive silencing of sFLT1 mRNA translated to a significant reduction in the amount of sFLT1 protein secreted by cytotrophoblasts into the cell medium (Fig. 1j) . hsiRNA sFLT1-i13 -2283 target sequences are conserved in human, baboons, and mouse; hsiRNA sFLT1-e15a -2519 target sequences are conserved in baboons and humans. We therefore selected these compounds for all subsequent studies.
hsiRNA sFLT1-i13 -2283 and siRNA sFLT1-e15a -2519 efficiently modulate expression of major sFLT1 mRNA isoforms without effect on full length FLT1 mRNA Successful therapeutic reduction of circulating sFLT1 in preeclampsia using hsiRNAs will require simultaneous suppression of all three sFLT1 (i13 short and long and e15a) mRNA isoforms (Fig. 1a,b and Supplementary Fig. 1 ). We therefore tested whether a mixture of isoform-specific hsiRNAs could be used to silence sFLT1-i13 and sFLT1-e15a mRNAs simultaneously. Using cytotrophoblasts and WM-115 cells (human melanoma cells that express sFLT1-i13 and sFLT1-e15a mRNAs), we confirmed that hsiRNA sFLT1 -2283 specifically silenced the sFLT1-i13 isoform and that hsiRNA sFLT1 -2519 specifically silenced the sFLT1-e15a isoform (Fig. 2a,b and Supplementary  Fig. 2 ). An equimolar mixture of the two (hsiRNA sFLT1 -2283/2519) efficiently silenced both sFLT1-i13 and sFLT1-e15a isoforms (Fig. 2a,b) . Neither the individual hsiRNAs nor the hsiRNA mixture affected the levels of full-length FLT1 mRNA (Fig. 2c) . Of note, the hsiRNA sFLT1 -2283/2519 mixture was more potent than individual hsiRNAs, with the effect being more pronounced for the sFLT1-i13 isoform. We have confirmed this phenomenon in several independent experiments.
Efficient in vivo delivery of fully chemically modified, cholesterol-conjugated hsiRNA sFLT1 -2283 to the placental labyrinth by systemic administration Productive systemic delivery of nonformulated hsiRNA to placenta had not been previously demonstrated. Although the partially modified siRNAs used for original screening could be taken up by cytotrophoblasts in vitro, these siRNAs failed to accumulate to appreciable levels in placenta after systemic administration ( Supplementary  Fig. 3) . We recently showed, however, that full chemical stabilization is essential for systemic, conjugate-mediated siRNA delivery 27 . We therefore synthesized fully chemically modified variants of lead compounds, in which all sugars were modified using an alternating 2′-fluoro and 2′-O-methyl modification pattern 39 . In addition, all 5′-and 3′-terminal linkages were phosphorothioate-modified, providing additional protection against exonucleases (Fig. 3a) . To visualize the A r t i c l e s extent of delivery to tissues in vivo, we labeled the passenger strand of hsiRNA sFLT1 -2283 with Cy3 fluorescent dye.
We injected Cy3-labeled hsiRNA sFLT1 -2283 into pregnant mice at gestational day 15, collected tissues 24 h after injection, and examined the tissue distribution of labeled hsiRNA by fluorescence microscopy. hsiRNA sFLT1 -2283 accumulated mainly in liver, kidneys, spleen and placental labyrinth (Fig. 3b) A r t i c l e s functions as a maternal-placental barrier and the site of nutrient transport between the maternal and fetal blood (Fig. 3b) . Consistent with the barrier function of the labyrinth, Cy3-labeled hsiRNA sFLT1 -2283 was detected only in placenta (Fig. 3c) . The labyrinth constitutes most of the placental disk, where fetal capillaries are supported by connective tissue and surrounded by trophoblast cells-mononuclear sinusoidal trophoblast giant cells and two layers of multinucleated syncytiotrophoblast cells. Notably, we observed efficient delivery of Cy3-labeled hsiRNA sFLT1 -2283 to the placental labyrinth, with no detectable uptake by other cell types in the decidua, the uterine endometrium that forms the maternal part of the placenta. Histological examination showed no obvious pathology associated with oligonucleotide delivery.
To quantify the accumulation of hsiRNA in placenta and other tissues, we used a recently developed peptide nucleic acid (PNA)-based hybridization assay to directly measure guide strand levels 23, 36 . Consistent with histological examination, fully chemically stabilized, cholesterol-conjugated hsiRNAs accumulated in maternal liver (~200 ng/mg), kidney (~50 ng/mg), spleen (~50 ng/mg) and placenta (10 to 20 ng/mg), but not in other fetal tissues (<0.05 ng/mg, detection limit) (Fig. 3d,e) . Notably, placental accumulation of hsiRNA was similar whether administered by subcutaneous or intravenous injection (Fig. 3b,d ,e). As much as 7% of injected hsiRNA sFLT1 -2283 accumulated in placentas, and the concentration of hsiRNA in the placenta was ~20 ng/mg, which was sufficient to induce productive silencing (Fig. 3d,e) .
In vivo silencing of placental-derived sFLT1 does not affect pup survival or ability to thrive Mice express only the sFlt1-i13 isoform 40 . Thus, we used hsiRNA sFLT1 -2283, which selectively silences sFlt1-i13, to test whether placental accumulation of hsiRNA results in productive sFLT1-i13 silencing. We injected 20 mg/kg hsiRNA sFLT1 -2283 in phosphate-buffered saline (PBS) intravenously into pregnant mice at gestational days 14 and 15 ( Fig. 4a) . Control animals were treated with PBS or a nontargeting control (NTC) hsiRNA NTC of identical chemical configuration (conjugated to cholesterol and with a 2′-O-methyl, 2′-fluoro alternating modification pattern, or hsiRNA sFLT1 -2283 lacking the cholesterol conjugate (NoC-siRNA sFLT1 -2283); Supplementary Table 1) . At gestational day 19, we measured sFlt1 mRNA levels in placenta. We observed a ~40% reduction of sFlt1 mRNA in placentas of mice treated with hsiRNA sFLT1 -2283 (P < 0.001, one-way ANOVA, relative to both PBS and hsiRNA NTC ; Fig. 4b ). The hsiRNA NTC was inactive, showing that sFlt1 silencing is specific to hsiRNA sFLT1 -2283. NoCsiRNA sFLT1 -2283 failed to accumulate in placenta ( Fig. 4c ) and consequently failed to silence sFlt1 mRNA ( Fig. 4b) , suggesting that full chemical stabilization and the cholesterol moiety are both required for placental delivery and silencing activity. We found no evidence for silencing of sFlt1 in fetal liver (data not shown), consistent with the histological and quantitative observations that hsiRNA sFLT1 -2283 did not accumulate in fetal tissues other than placenta (Fig. 3c,d, 
e).
Consistent with significant accumulation of hsiRNA sFLT1 -2283 in liver and kidney (Fig. 3d,e) , we also observed productive silencing of sFlt1 mRNA in both of these tissues ( Supplementary Fig. 4 ). In pregnant mice, however, >95% of circulating sFlt1 protein originates from placenta [40] [41] [42] . Thus, extraplacental silencing does not measurably contribute to reduced serum levels of sFLT1 in mice treated with hsiRNA sFLT1 -2283.
In a parallel study, we treated pregnant mice (at gestational days 14 and 15) with hsiRNA sFLT1 -2283 or PBS and collected blood samples at three time points during the third trimester to measure serum levels of sFlt1 protein by ELISA. In PBS-treated control mice, sFLT1 protein levels increased by about ~50% from day 14 to day 17 (near term). As expected, this increase was suppressed in mice treated with hsiRNA sFLT1 -2283 (Fig. 4d) as evidenced by blood sampling at gestational days 10, 15, 17 and 19 from mice injected with PBS or hsiR-NA sFLT1 -2283. At each time point, mice treated with hsiRNA sFLT1 -2283 had lower levels of circulating sFLT1 than did mice treated with PBS (P < 0.001, two-way ANOVA; Fig. 4d,j) or hsiRNA NTC (P < 0.05, two-way ANOVA; Fig. 4j) . Silencing of sFlt1 (up to 50%) or treating mice with hsiRNA NTC did not affect the number of newborn pups, their weight at birth, or their ability to thrive ( Supplementary  Fig. 5a-e) . Moreover, levels of the maternal liver transaminases ALT and AST were normal (Fig. 4e) , indicating that, at the doses tested, hsiR-NA sFLT1 -2283 treatment does not generate obvious adverse effects.
To confirm that the observed modulation of sFLT1 expression is indeed due to RNAi-based cleavage of sFlt1 mRNA, we purified total mRNA from placentas treated with hsiRNA sFLT1 -2283, hsiRNA NTC or PBS. The purified RNA was subjected to 5′-RACE-PCR amplification. The expected product size was observed only in hsiRNA sFLT1 -2283-treated samples, and sequencing confirmed the expected cleavage site (Supplementary Fig. 6 ). Taken together, these data show that systemic administration of hsiRNA sFLT1 -2283 leads to efficient RNAibased silencing of sFlt1 mRNA in the placenta and reduces the level of circulating sFLT1 protein without affecting the health of the mother or her pups. . M represents the molar concentration of hsiRNA; NTC, nontargeting control (****P < 0.0001, ***P < 0.001, *P < 0.05; ns, not significant; two-way ANOVA).
A r t i c l e s hsiRNA sFLT1 -2283/2519 mixture selectively silences sFLT1-i13 and sFLT1-e15a isoforms in vivo Our goal was to test whether the mixture of isoform-specific siRNAs effectively silences all three sFLT1 isoforms in a well-characterized nonhuman primate model of preeclampsia 43 . Before doing so, we measured the efficacy and safety of the hsiRNA sFLT1 -2283/2519 mixture in pregnant mice. An equimolar mixture of hsiRNA sFLT1 -2283/2519 injected into pregnant mice efficiently reduced sFlt1 mRNA in placenta (40%, P < 0.01, one-way ANOVA) and other maternal tissues (Fig. 4f) . hsiRNA sFLT1 -2283 and hsiRNA sFLT1 -2519 accumulated to nearly identical levels in the placenta, with no detectable transfer to the fetus (Fig. 4g) . hsiRNA sFLT1 -2283/2519 administration reduced circulating sFlt1 protein levels by day 17 (P < 0.001, two-way ANOVA) but did not affect pup viability, weight, or ability to thrive (data not shown), and maternal liver enzymes remained normal (Fig. 4h,i) . The observed reduction in sFlt1 was sequence specific, as hsiRNA NTC , compound with identical chemical configuration but not targeting sFlt1, had no impact on sFLT1 protein expression and was indistinguishable from PBS ( Fig. 4j) , with no observable effect on liver enzymes (Fig. 4k) . As expected, hsiRNA NTC treatment had no impact on number of pups or ability to thrive (Supplementary Fig. 5d,e) , confirming that this chemical scaffold was well tolerated at dose used. While most sFLT1 expression is derived from the placenta, sFLT1 is involved in fine-tuning regulation of VEGF signaling, specifically important for macular and corneal vascularization 44, 45 . We did not find any appreciable levels of the drug in the eye, and it is unlikely to have any biological consequences in that regard (Supplementary Fig. 7) .
We did not see any detectable levels of compound transfer to any additional fetal tissues by fluorescent microscopy (Fig. 3c) and PNA hybridization assay (Fig. 3d,e) . Breast is another heavily vascularized tissue in which hydrophobic siRNAs may accumulate. We observed around 2.5 ng/mg of hsiRNA sFLT1 compounds in breast tissue of nursing mice after hsiRNA treatment. This compound concentration was less than one-fifth that in the placenta of the same animals. No appreciable compound transfer was observed in milk (<1 ng/µL), indicating that chances for substantial neonatal hsiRNA accumulation in the pup via breast milk is minimal (Supplementary Fig. 7) .
Although our studies were not designed to formally evaluate pharmacokinetics, in our limited dataset, we were unable to detect A r t i c l e s appreciable concentrations of the drug in breast tissue or in milk. This in contrast to the robust levels of drug in the placental tissue. Additional pharmacokinetic studies in nonhuman primates are needed before we can conclude that the risk of breast milk excretion is low.
Finally, 40% to 50% sFLT1 repression in placenta might influence placental vascularization. In a subset of mice injected with the hsiRNA sFLT1 , we examined the placental tissue for vascular development and did not find any substantial vascular disruptions in the placental labyrinth (Supplementary Fig. 8 ) 46 . We can therefore conclude that injection of sFlt1 siRNA was therapeutic when injected during third trimester and at modest doses did not induce any notable vascular anomalies in the placenta. Although our studies do not show any obvious side effects in mothers or the fetuses, additional long-term safety studies will be needed before drawing definitive conclusion of the safety of this approach. Thus, co-delivery of hsiRNA sFLT1 -2283 and hsiRNA sFLT1 -2519 efficiently and safely reduced sFlt1 without affecting full-length Flt1 levels, recapitulating the pharmacological behavior observed with hsiRNA sFLT1 -2283 alone.
Single hsiRNA sFLT1 -2283/2519 injection efficiently modulates sFLT1 serum levels and reduces hypertension and proteinuria in a baboon model of preeclampsia Placental morphology and physiology differ between humans and mice, limiting the value of rodent models in mimicking human pathology. Placental morphology, maternal physiology, gestation (k) ALT and AST enzyme activities on E18 in mice injected in j. (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant; one-way ANOVA for b, c, e-g, i and k; two-way ANOVA for d, h and j).
A r t i c l e s
length and the immune system of baboons (Papio hamadryas), however, better resemble those of humans. P. hamadryas expresses all three sFLT1 mRNA isoforms, and an accepted preeclampsia model has been developed 43 . Thus, baboons represent a more accurate preclinical model in which to study efficacy, safety and toxicity of preeclampsia therapeutics. Induction of uteroplacental ischemia (UPI) in baboons via ligation of a single uterine artery at gestational day 133 (full term is 182 d) reduces placental blood flow by ~30%, causing a spike in sFLT1 levels and maternal hypertension and proteinuria, typical clinical manifestations of preeclampsia 43 . Continuous telemetry recordings can accurately measure blood pressure throughout the experiment, allowing real-time assessment of even subtle changes to this key metric. To assess the potential therapeutic benefit of the hsiRNA sFLT1 -2283/2519 mixture in the baboon UPI model of preeclampsia, we manufactured and purified ~4 g of hsiRNA sFLT1 -2283/2519 in-house and then confirmed its identity and purity by mass spectrometry. Working under approved animal safety protocols, we performed the following regimen. On gestational day 127, a telemeter was inserted into a pregnant baboon to continuously monitor blood pressure. On gestational day 133, we induced UPI and, within an hour of the surgery, injected an equimolar hsiRNA sFLT1 -2283/2519 mixture (10 mg/kg each hsiRNA, 20 mg/kg total, n = 3). Blood and urine were collected at regular intervals for 4 to 6 weeks (to term) to measure circulating sFLT1 protein, urinary protein, and standard blood chemistry markers (Fig. 5a) . The time points of sample collection varied slightly from animal to animal owing to the logistics of working with a free-living baboon colony. Control UPI animals (n = 6) were monitored for 14 d. Sham-operated animals (controls, n = 3) received a non-uterine artery ligation and were also monitored to term.
In hsiRNA sFLT1 -2283/2519-treated UPI animals, we observed a potent reduction in circulating sFLT1 protein, as compared to UPI control animals (Fig. 5b) , although the kinetics of sFLT1 reduction was somewhat variable. At ~2 weeks after injection in hsiRNA sFLT1 -2283/ 2519-treated baboons, serum sFLT1 levels were reduced by >50% (P < 0.001, two-way ANOVA), approaching the levels measured in sham-operated control baboons; these low levels were maintained through the end of the protocol. Again, similarly to sham-operated controls, hsiRNA sFLT1 -2283/2519-treated animals had lower blood pressure (Fig. 5c ) and reduced proteinuria (Fig. 5d) , consistent with potent reduction of sFLT1. Newborn baboon weights and centiles did not change significantly from control animals ( Supplementary  Fig. 9 ). However, we observed a trend toward lower birth weights in the offspring of baboons treated with hsiRNA sFLT1 , likely suggesting a pharmacological effect related to reduction in systemic blood pressure. Additional dose ranging studies with larger sample sizes will be needed to definitively assess whether the reduction in birth weights are related to sFLT1 repression. Thus, a single injection of hsiRNA sFLT1 -2283/2519 potently reduced serum levels of sFLT1 and normalized blood pressure and proteinuria, common clinical manifestations of preeclampsia.
To assess clearance of hsiRNA sFLT1 -2283 and hsiRNA sFLT1 -2519 from blood and their accumulation in tissues, we collected six or seven placental biopsies and one kidney biopsy from each baboon, in addition to the blood samples noted above. hsiRNAs exhibited similar pharmacological behavior, consistent with the expectation that hsiRNA distribution and clearance properties are mainly defined by the oligonucleotide chemical architecture rather than by sequence 20 . The kinetics of hsiRNA clearance from blood were similar in all three hsiRNA sFLT1 -2283/2519-treated baboons: serum hsiRNA levels remained constant and ranged from 100 to 300 ng/ml during the first 4 5 6 7 8 9 1 Figure 5 hsiRNA sFLT1 -2283/2519 treatment lowers sFLT1 serum levels and normalizes blood pressure and proteinuria in a baboon model of preeclampsia. (a) The timeline for uteroplacental ischemia induction (UPI) model of preeclampsia in pregnant baboon. Data collected for hsiRNA sFLT1 -2283/2519-treated UPI animals (n = 3, mean ± s.e.m.), PBS-treated UPI animals (n = 6, mean ± s.e.m.) and controls (sham surgery, no UPI) (n = 3, mean ± s.e.m.) (***P < 0.001, two-way ANOVA; UPI versus hsiRNA sFLT1 ). A r t i c l e s hour. By 24 h, most of the hsiRNA had been cleared from blood, with levels dropping to ~1 ng/ml. Residual hsiRNA was detected in blood (<0.1 ng/ml) throughout the study. After day 1, hsiRNA levels in urine remained below 0.5 ng/ml, and they fell below the limit of detection after approximately 30 d (Supplementary Fig. 10 ). Placental hsiRNA levels remained generally constant throughout the 4-to 6-week study duration (1.6 ± 0.3 ng/mg for siRNA sFLT1 -2283 and 2.6 ± 0.9 ng/mg for hsiRNA sFLT1 -2519, mean ± s.d., n = 3; Supplementary Fig. 10 ). hsiRNA levels in kidney biopsies, collected at day 14, were comparable to placental levels (1.8 ± 0.9 ng/mg for hsiRNA sFLT1 -2283, and 2.7 ± 1.4 ng/mg for hsiRNA sFLT1 -2519). Thus, the three-to fourfold difference in hsiRNA accumulation between placenta and kidney that we observed in mice does not hold true in baboons. Moreover, these findings show that persistent low levels of hsiRNA in placenta are sufficient to maintain therapeutic silencing of sFLT1 in this wellaccepted nonhuman primate model of preeclampsia.
DISCUSSION
Here we show that a single dose of hsiRNAs mediating silencing of sFLT1 provided therapeutic benefit in animal models of preeclampsia without adverse consequences to the developing fetus. Currently, iatrogenic birth often occurring preterm remains the only clinically accepted treatment for preeclampsia when maternal signs and symptoms become life threatening. Therapeutic strategies aimed at reducing circulating sFLT1 are being pursued as an avenue to treat and prevent severe preeclampsia 2,47-49 . Circulating sFLT1 can be removed from the maternal bloodstream by apheresis, thereby prolonging preeclamptic pregnancy, but this procedure is still in early-stage clinical trials 18, 19 . Moreover, apheresis is expensive and requires infrastructure that is only available in developed countries. To validate RNAi-based placental modulation of sFLT1 expression as a therapeutic approach, we chose a baboon model of preeclampsia that mimics many features of the human disease, including upregulation of placental sFLT1, a well-validated therapeutic target in preeclampsia 43 . Placental growth factor was recently used as a competitive inhibitor of sFLT1 in this baboon model of preeclampsia, reducing hypertension and proteinuria with safe progression to birth 50 . However, this approach does not target sFLT1 at its source and requires multiple protein injections. In contrast, our approach reduces sFLT1 in the placenta after a single injection. Physiological and anatomical similarities between humans and baboons make baboons an appropriate animal model for studying preeclampsia. Proof-of-concept studies in pregnant baboons therefore represent a key step toward clinical trials in humans 40 .
Advances in siRNA-based therapeutics, specifically in the area of liver diseases 21, 22 , recently resulted from two conceptual breakthroughs: extreme chemical stabilization of oligonucleotides 27, [51] [52] [53] and optimization of a trimeric GalNAc conjugate that drives selective uptake by hepatocytes 54, 55 . Fully chemically modified siRNAs provide unprecedented durability and sustained silencing activity-e.g., up to 9 months duration of effect after a single injection 21, 22 . The hydrophobic cholesterol conjugate supports siRNA delivery to a range of tissues, including liver, kidney, bone marrow, spleen, muscle and placenta (this study and refs. 23, [25] [26] [27] 35, 36, [56] [57] [58] . In mice, cholesterol-conjugated siRNA predominantly accumulated in liver and kidney, but up to 7% of the injected dose accumulated in placenta. The cholesterol moiety was essential for siRNA accumulation in placenta. Although the cholesterol conjugate does not provide selective delivery to placenta, delivery to a range of tissues allows functionally selective silencing when the intended target is a gene overexpressed in only one of those tissues. In the case of preeclampsia, sFLT1 is specifically overexpressed in placenta.
sFLT1 represents an exceptional target for siRNA-based therapeutics. Despite substantial effort, attempts to develop small molecules and antibodies that selectively downregulate sFLT1 have failedperhaps not surprisingly, since sFLT1 protein sequences are almost identical to the extracellular domain of full-length FLT1. Recently, a nanoparticle-formulated siRNA that nonselectively targets sFlt1 and full-length Flt1, with a ~1 mg/kg dose, was found to improve outcomes in a rat model of preeclampsia 59 . Nevertheless, rodents do not express the predominant isoform of sFLT1 mRNA made in humans, and systemic delivery of therapeutic siRNAs that target fulllength FLT1 could be a liability. Our approach, despite higher dosage, therefore takes advantage of FLT1 alternative polyadenylation, which creates a unique sequence space in sFLT1 mRNA isoforms that can be selectively targeted by siRNAs.
Our data suggest that a single injection of anti-sFLT1 hsiRNAs might suppress sFLT1 levels for several weeks, potentially extending pregnancy duration. In preeclampsia, extension of pregnancy by 2-4 weeks is of clinical significance, especially when the disease occurs preterm 1 . The desired level of sFLT1 silencing is only 30% to 40% (ref. 18) , with a higher degree of silencing being potentially disadvantageous owing to reduced uterine blood flow as a consequence of reduced blood pressure 18, 60 . We found that a 10 mg/kg dose produced >50% silencing in baboons, so dosing needs to be carefully titrated to tune sFLT1 silencing to the desired level. A strong relationship exists between hsiRNA dosing and the level and duration of target silencing 21 .
Notably, the initial phases of hsiRNA clearance were different in baboons and mice. In mice, >99% of hsiRNA was cleared within an hour after injection, but in baboons, hsiRNA blood levels remained constant during the first hour after injection (i.e., around 100 to 200 ng/ml at 15, 30 and 60 min). The rapid clearance of oligonucleotides in rodents compared to nonhuman primates has been previously reported for other classes of oligonucleotides 61, 62 and might reflect the higher metabolic rate of rodents 63 . Careful pharmacological studies are needed to define an optimal chemical composition, clinical dose and schedule to achieve the ideal level and duration of sFLT1 silencing.
Clinical utility also depends on an acceptable overall toxicity and safety profile. Complete knockdown of sFLT1 in trophoblasts with a lentivirally mediated shRNA approach has been associated with decidual hemorrhage 64 . However, at the doses tested (10 to 40 mg/kg), sFLT1 protein was reduced by 50%, which was not associated with adverse effects on blood chemistry; inflammatory markers; or pup viability, weight, vigor or placental vascularization. Notably, our data indicate that hsiRNAs administered during pregnancy are not transmitted to the fetal tissues other than placenta, minimizing concerns that sFLT1 silencing in the fetus would negatively affect fetal development or pup viability.
Preeclampsia is a disease with unmet medical need in both developed and underdeveloped countries. We show that siRNA-mediated silencing of sFLT1 mRNAs represents a viable path toward development of a preeclampsia therapeutic, particularly when the disease presents preterm. In dry form, siRNAs can be stored at ambient temperature for extended periods of time, they are relatively simple to manufacture, and they can be administered by subcutaneous injection. Thus, siRNA therapeutics potentially hold promise to address the needs of patients with preterm preeclampsia independently of economic status.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINE METHODS
hsiRNA design. We designed and synthesized a panel of 47 hsiRNA compounds targeting the human sFLT1-i13 and e15a mRNAs. These sequences span the unique sequence regions and were selected to comply with standard hsiRNA design parameters 31 including assessment of G+C content, specificity and low seed complement frequency 65 , elimination of sequences containing miRNA seeds, and examination of thermodynamic bias 33, 34 (Supplementary Table 1) . Synthesis of oligonucleotides. Oligonucleotides were synthesized using standard and modified (2′-F, 2′-O-Me) phosphoramidite solid-phase synthesis conditions using a MerMade 12 (BioAutomation, Irving, Texas) and Expedite DNA/RNA synthesizer (ABI 8909). Unconjugated oligonucleotide strands were grown on controlled pore glass (CPG) functionalized with a long-chain alkyl amine and Unylinker terminus (Chemgenes, N-4000-10), and cholesterol-conjugated oligonucleotides were synthesized on modified solid support (Chemgenes, N-9166-05). Oligonucleotides were removed from CPG, deprotected, and purified by HPLC as described previously 66 . Purified oligonucleotides were passed over a Hi-Trap cation exchange column to exchange the counterion with sodium.
Large-scale oligonucleotide synthesis was done on an AKTA Oligopilot 100 using standard protocols. Each synthesis was performed at the 200-µmol scale using Unylinker (ChemGenes, Wilmington, MA) for the antisense strand and a custom solid support containing a cholesterol-conjugated CPG for the sense strand. Phosphoramidites were prepared at 0.15 M concentrations for both the 2′-O-methyl (ChemGenes, Wilmington, MA) and 2′-fluoro (BioAutomation, Irving, Texas) amidites in acetonitrile. 5-(Benzylthio)-1H-tetrazole was used as the activator at 0.25 M. Detritylations were performed using 3% dichloroacetic acid in CH 2 Cl 2 . Capping was done with non-THF-containing reagents consisting of 20% N-methylimidazole in acetonitrile as capping reagent A and 20% acetic anhydride, 30% 2,6-lutidine in acetonitrile as capping reagent B. Sulfurization was performed with 0.1 M DTT in acetonitrile for 3 min. Phosphoramidite coupling times were 8 min for all amidites used. All oligonucleotides were confirmed by HPLC analysis and mass spectrometry.
Cell culture. HeLa and WM-115 cells were purchased from ATCC (ATCC, Manassas, VA; CCL-2, CLR-165). HeLa cells were maintained in Dulbecco′s Modified Eagle's Medium (Cellgro, Corning, NY; 10-013CV) supplemented with 10% FBS (Gibco, Carlsbad, CA; 26140) and 100U/ml penicillin/ streptomycin (Invitrogen, Carlsbad, CA; 15140) and grown at 37 °C in 5% CO 2 . Cells were split every 2 to 5 d and discarded after 15 passages. WM-115 cells were maintained in Eagle's Minimum Essential Medium (Gibco, Carlsbad, CA; 11095) supplemented with 2 mM glutamine, 1% nonessential amino acids, 1% sodium pyruvate, 10% FBS (all from Gibco) and 100 U/mL penicillin/streptomycin (Invitrogen) and grown at 37 °C in 5% CO 2 . Cells were split every 2 to 4 d. CTBs were isolated from human placenta (under BIDMC IRB protocol number 2009-000317, PI: S.A.K.) and were cultivated as described previously 42, 67 . Isolated CTB cells were maintained in M199 medium (Gibco, Carlsbad, CA; 11043023) with 10% FBS.
Direct delivery (passive uptake) of oligonucleotides. For initial hsiRNA library screening, cDNA sequences corresponding to unique regions of human sFLT1 i13 and e15a (435 and 567 bp) were cloned into psiCheck-2 vector (Promega, Madison, WI; C8021) and a DualGlo luciferase assay system was used (Promega, Madison, WI; E2920) according to the manufacturer's manual. Briefly, HeLa cells on a 10-cm dish were transfected with psiCheck-2-i13 or psiCheck-2-e15a plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA; 11668019) according to the manufacturer's manual. Cells were plated 24 h later in DMEM containing 6% FBS at 10,000 cells per well in 96-well cell culture plates. hsiRNA was diluted to twice the final concentration in OptiMEM (Carlsbad, CA; 31985-088), and 50 µL diluted hsiRNA sFLT1 or hsiRNA NTC (NTC, nontargeting control) were added to 50 µL of cells, resulting in 3% FBS final. Cells were incubated for 72 h at 37 °C and 5% CO 2 . The primary screen for active hsiRNAs was performed at 1.5-3 µM compound, which also served as the maximal dose for in vitro dose response assays. To test hsiRNAs in CTB and WM-115 cells, cells were plated at 20,000-30,000 cells per well in 96-well plates in M199 or EMEM media containing 3% FBS and treated with hsiRNAs for 72 h. mRNA quantification in cells and tissue punches. mRNA was quantified from both cells and tissue punches using the QuantiGene 2.0 assay kit (Affymetrix, QS0011) as described previously 68, 69 . Cells were lysed in 250 µL diluted lysis mixture composed of one part lysis mixture (Affymetrix, 13228), two parts H 2 O and 0.167 µg/µL proteinase K (Affymetrix, QS0103) for 30 min at 55 °C. Cell lysates were mixed thoroughly, and 40-80 µL of each lysate was added per well of a capture plate with 20 µL diluted lysis mixture without proteinase K. Probe sets for human FLT1, sFLT1-i13, sFLT1-e15a, PPIB and YWHAZ (Affymetrix; SA-50494, SA-50495, SA-50496,SA-10003, SA-13271) or mouse Flt1, sFlt1 and Ppib (Affymetrix; SB-50048, SB-50049, SB-10002) were diluted and used according to the manufacturer's recommended protocol. Datasets were normalized to Ppib or Flt1.
For analysis of mRNA in mouse tissues, tissue punches (2-5 mg) were homogenized in 300-400 µL of homogenizing buffer (Affymetrix, 10642) containing 2 µg/µL proteinase K in 96-well plate format on a Qiagen TissueLyser II, and 20-60 µL of each lysate was added to a bDNA capture plate. Diluted probe sets were added to each well of the capture plate for a final volume of 100 µL. Signal was amplified according to the Affymetrix protocol. Luminescence was detected on a Veritas luminometer (Promega, Madison, WI; 998-9100) or Tecan M1000 (Tecan, Morrisville, NC).
Probe sets for baboon FLT1, sFLT1-i13, sFLT1-e15a and HPRT (Affymetrix; SF-10775, SF-10778, SF-10779, SF-10776) were used for baboon FLT1 and sFLT1 mRNA analysis.
Fluorescence imaging. Mice were injected intravenously (tail vein) or subcutaneously (interscapularly) with 10 mg/kg of Cy3-labeled hsiRNA. After 24 h, mice were killed and tissues were removed, embedded in paraffin, and sliced into 4-µm sections that were mounted on glass slides. Sections were deparaffinized by incubating in xylene twice for 8 min. Sections were rehydrated in serial ethanol dilutions (100%, 95% and 80%) for 4 min each and then washed twice for 2 min with PBS and stained with DAPI. All fluorescence images were acquired with a Leica DMi8 inverted tiling microscope (Leica Microsystems). Images were processed using the Leica software suite (LAS X and LAS X Lite, Leica Microsystems).
ELISA and AST and ALT assays. ELISA for human and mouse sFLT1 was performed according to the manufacturer's instructions (R&D Systems; Quantikine FLT1, MVR100). All assays were done in duplicate, and protein levels were calculated using a standard curve derived from known concentrations of the respective recombinant proteins. AST and ALT activities in mouse serum were measured according to the manufacturer's instructions using colorimetric assay kits (Sigma; MAK055 and MAK052).
PNA hybridization assay. hsiRNA guide (antisense) strand accumulation in mouse tissues was quantified using a PNA hybridization assay, as described previously 23 . Briefly, tissue punches were homogenized in MasterPure Tissue Lysis Solution (EpiCentre) with added proteinase K (2 mg/mL, Invitrogen) and homogenized using a TissueLyser II (Qiagen), using 100 µL of lysis solution per 10 mg tissue. Following lysis, sodium dodecyl sulfate (SDS) was precipitated with KCl (3 M) and cleared supernatant was hybridized to a Cy3-labeled PNA oligonucleotide fully complementary to the guide strand (PNABio). This mixture was analyzed by high-performance liquid chromatography (HPLC). Cy3-labeled peaks were integrated and plotted on an internal calibration curve. The mobile phase for HPLC was 50% water, 50% acetonitrile, 25 mM TrisHCl (pH 8.5) and 1 mM ethylenediamine tetraacetate. The salt gradient was 0-800 mM NaClO 4 .
Animals, efficacy and safety. Wild-type C57BL/6J or pregnant CD1 mice were purchased from Jackson Laboratory (Bar Harbor, ME). All animal procedures were approved by the University of Massachusetts Medical School Institutional Care and Use of Animals Committee (IACUC, protocol number A-2411) or the Beth Israel Deaconess Medical Center IACUC (protocol number 048-2017). Mice were 6 to 10 weeks old at the time of experiments. All animals were kept on a 12-h light/dark cycle in a pathogen-free facility, with food and water provided ad libitum.
Four 2.0-mm punches per side were made, three processed individually for the QuantiGene 2.0 assay (Affymetrix, QS0011). For systemic
